ICER provides cost-effective pricing ballpark for unpriced SMA drug

The Institute for Clinical and Economic Review (ICER) released late Thursday its draft evidence report for spinal muscular atrophy therapies, suggesting a staggering difference in incremental cost effectiveness vs. best supportive care between Zolgensma onasemnogene abeparvovec (AVXS-101) from Novartis AG (NYSE:NVS; SIX:NOVN) and Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB).

Accounting for

Read the full 507 word article

User Sign In